Loncar China Biopharma ETF (NASDAQ:CHNA – Get Rating)’s stock price dropped 2.5% during mid-day trading on Wednesday . The stock traded as low as $16.84 and last traded at $16.84. Approximately 218 shares were traded during trading, a decline of 64% from the average daily volume of 600 shares. The stock had previously closed at $17.27.
Loncar China Biopharma ETF Price Performance
The business has a 50-day simple moving average of $17.82 and a 200 day simple moving average of $18.44.
Hedge Funds Weigh In On Loncar China Biopharma ETF
A hedge fund recently bought a new stake in Loncar China Biopharma ETF stock. OLD Mission Capital LLC bought a new position in Loncar China Biopharma ETF (NASDAQ:CHNA – Get Rating) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 4,620 shares of the company’s stock, valued at approximately $87,000. OLD Mission Capital LLC owned approximately 1.54% of Loncar China Biopharma ETF as of its most recent filing with the Securities & Exchange Commission.
Loncar China Biopharma ETF Company Profile
The Loncar China BioPharma ETF (CHNA) is an exchange-traded fund that is based on the Loncar China BioPharma index. The fund tracks a tier-weighted index of companies directly involved in the growth of Chinas pharmaceutical and biotech industry. CHNA was launched on Aug 14, 2018 and is managed by Loncar.
- Get a free copy of the StockNews.com research report on Loncar China Biopharma ETF (CHNA)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for Loncar China Biopharma ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loncar China Biopharma ETF and related companies with MarketBeat.com's FREE daily email newsletter.